Faruqi & Faruqi, LLP Announces the Investigation of ZS Pharma, Inc. (ZSPH) Over the Proposed Sale of the Company to AstraZeneca PLC
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ZS Pharma, Inc. (“ZS” or the “Company”) (NasdaqGM:ZSPH) for potential breaches of fiduciary duties in connection with the sale of the Company to AstraZeneca PLC for approximately $2.7 billion.
The Company’s stockholders will only receive $90.00 in cash for each share of Company common stock they own. However, the offer is below at least one analyst’s target price of $110.00 per share.
If you own common stock in ZS and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.